

14 July 2023

Treatment of lung cancer

Q1 - How many patients has your Trust treated in the past 3 months for:

We have provided the information we can collate from the following systems CaPPs, RISOH and ARIA, For further information a manual notes review would take more than 18 hrs to complete)

- **Non-small cell lung cancer (NSCLC) - any treatment:** We are unable to determine if there are any other additional patients who have received other treatments without completing an extensive trawl of patient notes. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information
- **Non-small cell lung cancer (NSCLC) - surgical treatment:** From March to May 2023 we can confirm that 41 patients with NSCLC had surgical treatment.
- **Non-small cell lung cancer (NSCLC) – radiotherapy:** 160 patients referred and treated
- **Non-small cell lung cancer (NSCLC) - systemic anti-cancer treatment (SACT):** 46 patients treated (RISOH)

Q2 - How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

We have provided the information we can collate from the following systems CaPPs, RISOH and ARIA.

For further information an extensive trawl of patient notes would be required. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information

Details from RISOH follows:

- ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) Lorlatinib: <5 cycle <5
- Amivantamab

14 July 2023

- Atezolizumab monotherapy: <5 (<5 cycle 1, <5 mid regimen)
- Atezolizumab with chemotherapy: Atez/Bev/Carbo/Pac <5 cycle 1
- Dabrafenib + Trametinib
- Durvalumab: 5 (<5 cycle 1, <5 mid regimen)
- Gemcitabine Gem/Carbo: <5 mid regimen
- Nitendanib + Docetaxel
- Nivolumab
- Osimertinib: 8 (<5 cycle 1, 7 mid regimen)
- Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib)
- Paclitaxel
- Pembrolizumab monotherapy: 12 (5 cycle 1, 7 mid regimen)
- Pembrolizumab with chemotherapy Pembro/Pemetrexed/Carbo: <5 mid regimen
- Pemetrexed with carboplatin/cisplatin
- RET Inhibitors (Pralsetinib, Selpercatinib)
- Sotorasib
- Tepotinib
- Vinorelbine monotherapy or combination with Carboplatin/Cisplatin: Carbo/Vin - 6 cycle 1, Cis/Vin -6 (<5 cycle 1 + <5 mid regimen), Cis/Vin/XRT -<5 cycle 1
- Other active systemic anti-cancer therapy [please state]
- Palliative care only

Q3 - Of the NSCLC patients treated with Nivolumab in the past 3 months, how many patients received (surgery) or are scheduled to receive surgical treatment after commencement of the treatment with Nivolumab?

The information requested is not collated centrally and an extensive trawl of patient notes would be required. We estimate that compliance with this request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information